Pfizer Inc (MIL:1PFE)
€ 25 -0.395 (-1.56%) Market Cap: 140.28 Bil Enterprise Value: 192.77 Bil PE Ratio: 36.11 PB Ratio: 1.64 GF Score: 63/100

Pfizer Inc at Wolfe Research Healthcare Conference (Virtual) Transcript

Nov 17, 2021 / 05:30PM GMT
Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research

Okay. I think we've begun here. So thanks for joining us. I'm Tim Anderson. I'm the large-cap pharma and biotech analyst at Wolfe Research.

Today is the first day of our 2 day healthcare conference, where we'll be interviewing different companies in a fireside chat format.

We've got Pfizer with us for this next session. 3 members of the R&D team, Mikael Dolsten, President, Worldwide R&D, Chief Medical Officer. He came to Pfizer through the Wyeth acquisition in 2009. We have Annaliesa Anderson, who is SVP and Chief Scientific Officer in Bacterial Vaccines and Hospitals. She's been with the organization since 2007. We have Charlotte Allerton, SVP and Head of Medicine Design with the company since 1993. And we have Chris Stevo from Investor Relations. And Chris, I think you want to make some opening remarks here.

Christopher J. Stevo
Pfizer Inc. - Senior VP & Chief IR Officer

Yes, I'm not a scientist, so all I'm good for is reading forward-looking statements. So I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot